Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response. - Wikidata - wikimedia - TriplyDB

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

http://www.wikidata.org/entity/Q34458745

about

BH3 Profiling Reveals Selectivity by Herpesviruses for Specific Bcl-2 Proteins To Mediate Survival of Latently Infected Cells.

P2860

Q35641404-094791DE-6DC0-404C-ADF2-15CCAC1C51E2

P2860

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.

http://www.wikidata.org/entity/Q34458745

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Mitochondrial priming of chron ...... dence with alvocidib response.

@ast

Mitochondrial priming of chron ...... dence with alvocidib response.

@en

Mitochondrial priming of chron ...... dence with alvocidib response.

@nl

type

label

Mitochondrial priming of chron ...... dence with alvocidib response.

@ast

Mitochondrial priming of chron ...... dence with alvocidib response.

@en

Mitochondrial priming of chron ...... dence with alvocidib response.

@nl

prefLabel

Mitochondrial priming of chron ...... dence with alvocidib response.

@ast

Mitochondrial priming of chron ...... dence with alvocidib response.

@en

Mitochondrial priming of chron ...... dence with alvocidib response.

@nl

P1433

Q34458745-42AD78E1-A525-4FCC-90FB-05AF50CEFF6F

P1476

Q34458745-95749639-E858-45C3-A184-9D3B3F80C7FD

P2093

Q34458745-29B79854-2BFF-4BA4-857E-6078A65F6BA2

Q34458745-4896E770-30C0-4748-8521-C6F6500FAFCF

Q34458745-4A77C937-3F70-43E6-8DD5-12741E739CDB

Q34458745-68745A19-2D1B-40D0-A2EE-BF0A6EE17B07

Q34458745-7FB434C2-DEF0-458D-9D71-38D719CF3F9D

Q34458745-8EB11800-BBB5-4C5E-86E6-BF3D6C4E2F95

Q34458745-B2C7C081-61CA-412B-822D-549B0A6F5F1D

Q34458745-BBF99F88-AE0C-4923-966D-1B2E22303179

Q34458745-C1A75321-90B2-4BCD-9DF0-FD81BB1F6D86

Q34458745-E2770708-0A3B-416C-999C-A3C2A16B23EC

P2860

Q34458745-0EC034F4-6C2E-49FE-B548-FC7E4780FBE7

Q34458745-1846B426-2DB3-46EF-AFD6-82719102636C

Q34458745-3AD82960-6F31-44B0-A488-E2C033B71E3E

Q34458745-3DD45F99-0402-46BB-9F82-BA2BF398652A

Q34458745-484181B3-247B-45C8-A2AB-9CA413EF8CF7

Q34458745-4B7FA93D-661B-49F3-B031-A932CCB6D1AF

Q34458745-5250461C-3F41-4A25-AB7E-8F9FC37952AF

Q34458745-5C2B55EA-5288-4436-98C0-630AEFAEA1D7

Q34458745-654AAF62-8C52-4806-A7DC-E43DFBAD9DAA

Q34458745-6D86FAC6-0459-476D-8AA9-A39692C8B2DB

P2888

Q34458745-0F396584-E22B-4AED-A771-692728059DA9

P304

Q34458745-A7D85EE3-9D21-4605-92DB-87E14F827C6D

P31

Q34458745-4DE8C38F-3644-4129-A050-57C159ADDA27

P356

Q34458745-75D36601-16C0-4C58-A8CB-063F7E1C331D

P433

Q34458745-D2F24950-4163-405C-9284-8FBECB96BDD0

P478

Q34458745-086C9709-4CE3-458E-A896-92E4365955F5

P50

Q34458745-8D279680-D625-45E9-BA8D-FC678BED9FAE

P577

Q34458745-E2FE65B7-027D-4929-871B-01EF6CA31FB3

P5875

Q34458745-04976B95-1D8F-4A03-A60E-8D81AAAFFAC9

P6179

Q34458745-E9B7D68E-1C98-4948-A04E-0444D7013418

P698

Q34458745-A28A4B4B-746B-41B4-AFCE-135D313E36DB

P932

Q34458745-107BABBD-E366-4930-B1FF-0B1C7008ED5F

P356

P1433

P1476

Mitochondrial priming of chron ...... dence with alvocidib response.

@en

P2093

A J Johnson

http://www.w3.org/2001/XMLSchema#string

C Doykan

http://www.w3.org/2001/XMLSchema#string

D V Hoff

http://www.w3.org/2001/XMLSchema#string

J C Byrd

http://www.w3.org/2001/XMLSchema#string

L Andritsos

http://www.w3.org/2001/XMLSchema#string

M C Lanasa

http://www.w3.org/2001/XMLSchema#string

M Elashoff

http://www.w3.org/2001/XMLSchema#string

M H Cardone

http://www.w3.org/2001/XMLSchema#string

M R Grever

http://www.w3.org/2001/XMLSchema#string

N Blake

http://www.w3.org/2001/XMLSchema#string

P2860

Genomic aberrations and survival in chronic lymphocytic leukemia

Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients.

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

NOTCH1 mutations in CLL associated with trisomy 12.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.

CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

P2888

P304

2251-2254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2014.206

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

David J. Bearss

P577

2014-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263745747

http://www.w3.org/2001/XMLSchema#string

P6179

1034852717

http://www.w3.org/2001/XMLSchema#string

P698

24990615

http://www.w3.org/2001/XMLSchema#string

P932

4221486

http://www.w3.org/2001/XMLSchema#string